Plasma neurofilament light chain concentrations are elevated in youth‐onset type 2 diabetes and associated with neuropathy

The lack of easily measurable biomarkers remains a challenge in executing clinical trials for diabetic neuropathy (DN). Plasma Neurofilament light chain (NFL) concentration is a promising biomarker in immune‐mediated neuropathies. Longitudinal studies evaluating NFL in DN have not been performed.

[1]  W. Rathmann,et al.  Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy , 2022, Diabetologia.

[2]  Gian-Andrea Thanei,et al.  Development of an age‐adjusted model for blood neurofilament light chain , 2022, Annals of clinical and translational neurology.

[3]  R. Burgess,et al.  A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease , 2021, Journal of the peripheral nervous system : JPNS.

[4]  N. White,et al.  Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. , 2021, Diabetes care.

[5]  C. Teunissen,et al.  Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials , 2021, Neurotherapeutics.

[6]  Bereket T. Tesfaldet,et al.  Long-Term Complications in Youth-Onset Type 2 Diabetes. , 2021, The New England journal of medicine.

[7]  R. Lanzenberger,et al.  Seven day pre-analytical stability of serum and plasma neurofilament light chain , 2021, Scientific Reports.

[8]  M. Katsuno,et al.  Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients , 2021, Journal of Neurology.

[9]  H. Potter,et al.  Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease , 2021, Neurobiology of Aging.

[10]  David Steven Scott,et al.  Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease , 2021, Alzheimer's & dementia.

[11]  David John Adams,et al.  Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis , 2020, Neurology.

[12]  Jae-Won Hyun,et al.  Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy , 2020, Scientific Reports.

[13]  A. Lleó,et al.  Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  L. Schöls,et al.  NfL and pNfH are increased in Friedreich’s ataxia , 2020, Journal of Neurology.

[15]  Amy S. Shah,et al.  Heart Rate Variability and Cardiac Autonomic Dysfunction: Prevalence, Risk Factors, and Relationship to Arterial Stiffness in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study , 2019, Diabetes Care.

[16]  J. Sussman,et al.  Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus. , 2019, Stroke.

[17]  P. Calabresi,et al.  Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  G. Cantalupo,et al.  Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis , 2019, Journal of Neurology.

[19]  Amy S. Shah,et al.  Youth-Onset Type 2 Diabetes and the Developing Brain , 2019, Current Diabetes Reports.

[20]  V. Srikanth,et al.  Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study , 2018, Diabetologia.

[21]  J. Divers,et al.  Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study , 2018, Pediatric diabetes.

[22]  T. Derfuss,et al.  Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy , 2017, Annals of the rheumatic diseases.

[23]  S. Saydah,et al.  Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study , 2017, Diabetes Care.

[24]  Ludwig Kappos,et al.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.

[25]  B. Larijani,et al.  Association of diabetes mellitus and structural changes in the central nervous system in children and adolescents: a systematic review , 2017, Journal of Diabetes & Metabolic Disorders.

[26]  M. Banerjee,et al.  Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status , 2016, Diabetes Care.

[27]  Henrik Zetterberg,et al.  Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction , 2015, PloS one.

[28]  M. Zhan,et al.  Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. , 2015, Journal of diabetes and its complications.

[29]  Jasmin Divers,et al.  Peripheral Neuropathy in Adolescents and Young Adults With Type 1 and Type 2 Diabetes From the SEARCH for Diabetes in Youth Follow-up Cohort , 2013, Diabetes Care.

[30]  J. Albers,et al.  Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[31]  B. Frier,et al.  Diabetes and cognitive dysfunction , 2012, The Lancet.

[32]  W. Tamborlane,et al.  Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes , 2007, Pediatric diabetes.

[33]  Ali Moghtaderi,et al.  Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy , 2006, Clinical Neurology and Neurosurgery.

[34]  A. Petzold.  Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss , 2005, Journal of the Neurological Sciences.

[35]  Braxton D Mitchell,et al.  The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. , 2003, Diabetes care.

[36]  M B Brown,et al.  A Practical Two-Step Quantitative Clinical and Electrophysiological Assessment for the Diagnosis and Staging of Diabetic Neuropathy , 1994, Diabetes Care.